Strong Revenue Growth and Market Expansion Drive Buy Rating for MannKind

In a report released today, Yun Zhong from Wedbush maintained a Buy rating on MannKind (MNKD – Research Report), with a price target of $11.00.

Yun Zhong has given his Buy rating due to a combination of factors including the strong revenue growth reported by MannKind’s partner, United Therapeutics, for Tyvaso DPI. The revenue for the first quarter of 2025 showed a significant increase compared to both the previous quarter and the same quarter last year, driven by a rise in patient numbers and a pricing adjustment.
Additionally, the utilization of Tyvaso DPI by patients with pulmonary hypertension associated with interstitial lung disease has been a key growth driver, with expectations for continued momentum. The ongoing TETON studies, which are expected to provide top-line data in the coming years, could potentially expand Tyvaso’s market, further supporting the positive outlook for MannKind’s stock.

According to TipRanks, Zhong is an analyst with an average return of -21.4% and a 31.02% success rate. Zhong covers the Healthcare sector, focusing on stocks such as Protagonist Therapeutics, Ascendis Pharma, and MannKind.